Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.55 USD
Change Today +0.03 / 0.18%
Volume 85.0K
ICEL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

cellular dynamics internatio (ICEL) Snapshot

Open
$16.49
Previous Close
$16.52
Day High
$16.58
Day Low
$16.48
52 Week High
04/17/15 - $16.90
52 Week Low
12/12/14 - $4.72
Market Cap
261.7M
Average Volume 10 Days
106.8K
EPS TTM
$-1.94
Shares Outstanding
15.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLULAR DYNAMICS INTERNATIO (ICEL)

Related News

No related news articles were found.

cellular dynamics internatio (ICEL) Related Businessweek News

No Related Businessweek News Found

cellular dynamics internatio (ICEL) Details

Cellular Dynamics International, Inc. develops and manufactures human cells in the United States, Europe, Japan, and internationally. The company’s proprietary products include human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and iCell Neurons that are purified human neurons typical of the forebrain for pre-clinical drug discovery, neurotoxicity testing, and disease modeling for Alzheimer’s diseases, Parkinson’s diseases, Huntington’s diseases, and others. The company also provides iCell DopaNeurons, purified human midbrain dopaminergic neurons essential for controlling complex behaviors; iCell Endothelial cells, which are interior surface blood vessel cells for use in vascular biology research, such as angiogenesis, atherosclerosis, inflammation, and other life science research; and iCell Hepatocytes that are human liver cells for pre-clinical drug discovery, hepatotoxicity testing, disease modeling, and other life science research. In addition, it offers MyCell products for making iPSCs for stem cell banking, cell modeling of specific ethnic or disease populations, and genetic engineering for in vitro research; and media and reprogramming kits for making iPSCs for limited research use. The company serves biopharmaceutical companies, government research institutions, academic and nonprofit research institutions, contract research organizations, and stem cell banks. Cellular Dynamics International, Inc. was founded in 2004 and is headquartered in Madison, Wisconsin.

155 Employees
Last Reported Date: 03/5/15
Founded in 2004

cellular dynamics internatio (ICEL) Top Compensated Officers

Founder, Chairman of the Board and Chief Exec...
Total Annual Compensation: $475.0K
Founder, Vice Chairman and President
Total Annual Compensation: $475.0K
Chief Operating Officer and Vice President of...
Total Annual Compensation: $360.0K
Chief Commercial Officer and Vice President o...
Total Annual Compensation: $344.0K
Compensation as of Fiscal Year 2013.

cellular dynamics internatio (ICEL) Key Developments

Shareholders of Cellular Dynamics International Files Class-Action Lawsuit to Block $307 Million Sale of the Company to a Japanese Company

Shareholders of Cellular Dynamics International filed a class-action lawsuit seeking to block a $307 million sale of the company to a Japanese company. Fujifilm Holdings Corp. is seeking to acquire Cellular Dynamics. The lawsuit, filed in Dane County Circuit Court, claims the sale favors the Cellular Dynamics board and senior management, who own about 23.7% of shares, to the detriment of other shareholders.

Cellular Dynamics International, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:35 PM

Cellular Dynamics International, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:35 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: Robert J. Palay, Founder, Chairman of the Board and Chief Executive Officer.

Cellular Dynamics International, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Cellular Dynamics International, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $6,550,000 compared to $4,159,000 a year ago. Loss from operations was $5,412,000 compared to $6,367,000 a year ago. Net loss was $5,771,000 compared to $6,713,000 a year ago. Basic and diluted net loss per share was $0.36 compared to $0.43 a year ago. For the full year, the company reported total revenue of $16,692,000 compared to $11,884,000 a year ago. Loss from operations was $29,253,000 compared to $24,263,000 a year ago. Net loss was $30,597,000 compared to $24,958,000 a year ago. Basic and diluted net loss per share was $1.94 compared to $3.17 a year ago. The company invested $3.1 million in property, plant and equipment. Nearly half of this investment occurred in California. Capital expenditures in California amounted to $1.3 million for 2014. Other capital expenditures during the year related to the completion of additional laboratory space in Madison, Wisconsin and to improvements in the company's IT and network infrastructure. The bulk of the revenue was for sales in the in vitro market. The growth in both periods total revenues resulted from an increase in Collaborations, partnerships and other revenues.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICEL:US $16.55 USD +0.03

ICEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $5.43 USD +0.30
General Electric Co $27.31 USD +0.23
Lonza Group AG SFr.133.10 CHF +1.00
ReproCELL Inc ¥669.00 JPY -2.00
Sigma-Aldrich Corp $138.94 USD +0.02
View Industry Companies
 

Industry Analysis

ICEL

Industry Average

Valuation ICEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.7x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLULAR DYNAMICS INTERNATIO, please visit www.cellulardynamics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.